Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience director Melissa A. Starovasnik executed an open-market sale of 1,000 shares of Common Stock at $51.00 per share on April 1, 2026. After the transaction, she directly holds 25,722 shares of Twist Bioscience common stock.
The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the transaction was planned in advance rather than timed discretionarily.
The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting 03/13/2026 activity for Twist Bioscience Corp common stock. The filing states that, after an internal realignment effective 01/12/2026, certain Vanguard subsidiaries will report ownership separately under SEC Release No. 34-39538. The filing shows amount beneficially owned: 0 and percent of class: 0%. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Twist Bioscience Corp officer Dennis Cho reported a mandated sale of 354 shares of Common Stock at $43.7864 per share to cover tax withholding on vesting Restricted Stock Units. After this sell-to-cover transaction, Cho directly holds 137,903 Twist Bioscience shares.
Twist Bioscience Corp senior vice president of human resources Paula Green reported a small sale of common stock tied to taxes on vested Restricted Stock Units. She sold 297 shares at an average price of $43.7864 per share through a mandated “sell to cover” transaction under the company’s equity incentive plans. After this tax-related sale, she directly holds 124,104 shares of Twist Bioscience common stock. The footnote explains that the transaction was required to satisfy tax withholding obligations and did not reflect a discretionary trading decision by the executive.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a small mandated share sale tied to tax withholding. On 2026-03-20, she sold 1,742 shares of common stock at an average price of $43.7864 per share to cover taxes due on vesting restricted stock units, as required under the company’s equity incentive plans and not as a discretionary trade. Following this transaction, she continued to hold 858,887 shares of common stock directly and also held employee stock options, including an award exercisable for 64,950 shares at an exercise price of $67.8500 expiring on 2030-08-31.
TWST filing reports a Form 144 notice for the proposed sale of Common Stock. The filing lists 1,742 shares tied to restricted stock vesting with a transaction date of 03/19/2026. The filing also reports recent dispositions by Emily M. Leproust: 1,605 shares on 12/22/2025, 5,001 shares on 02/03/2026, 7,205 shares on 02/23/2026, and 2,423 shares on 03/06/2026.
TWST submitted a Rule 144 notice reporting the proposed resale of 354 shares of Common Stock tied to 03/19/2026 restricted stock vesting.
The excerpt also lists recent open-market sales by Dennis H. Cho during the prior three months: 324 shares on 12/22/2025, 1,099 shares on 02/03/2026, 5,000 shares on 02/11/2026, 844 shares on 02/23/2026, and 425 shares on 03/06/2026, with proceeds shown alongside each trade in the excerpt.
TWST disclosed a Form 144 reporting multiple insider sales by Paula Green. The largest listed sale was 39,404 shares on 02/17/2026 for $2,064,751.13. Other reported dispositions: 1,194 shares on 02/03/2026 ($55,611.15), 1,465 shares on 02/23/2026 ($68,429.85), 935 shares on 03/06/2026 ($43,408.50), and 273 shares on 12/22/2025 ($9,433.79).
The filing also shows 297 restricted shares vesting as compensation on 03/19/2026. All amounts and dates are taken from the disclosed transactions.
Twist Bioscience director Robert Chess exercised stock options for 10,000 shares of Common Stock at $11.89 per share and on the same day sold 10,000 shares at $47.00 per share in an open-market transaction. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance. After the sale, he holds 21,084 shares directly and 42,528 shares indirectly through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.